Meyka Pro banner
Alkermes plc

Alkermes plc Fundamental Analysis (NASDAQ: ALKS)

ALKS●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$47.89
$1.42(3.06%)
U.S. Market opens in 12h 58m

Alkermes plc Fundamental Analysis (NASDAQ: ALKS)

Alkermes plc (NASDAQ: ALKS) shows weak financial fundamentals with a PE ratio of 15864.70, profit margin of -0.02%, and ROE of -0.02%. The company generates $1.8B in annual revenue with weak year-over-year growth of -5.25%.

Key Strengths

PEG Ratio-158.88
Current Ratio2.42

Areas of Concern

ROE-0.02%
Operating Margin3.66%
We analyze ALKS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 18.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
18.3/100

We analyze ALKS's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALKS struggles to generate sufficient returns from assets.

ROA > 10%
-0.01%

Valuation Score

Moderate

ALKS shows balanced valuation metrics.

PE < 25
15864.70
PEG Ratio < 2
-158.88

Growth Score

Weak

ALKS faces weak or negative growth trends.

Revenue Growth > 5%
-5.25%
EPS Growth > 10%
-33.78%

Financial Health Score

Excellent

ALKS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.84
Current Ratio > 1
2.42

Profitability Score

Weak

ALKS struggles to sustain strong margins.

ROE > 15%
-1.94%
Net Margin ≥ 15%
-0.02%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ALKS Expensive or Cheap?

P/E Ratio

ALKS trades at 15864.70 times earnings. This suggests a premium valuation.

15864.70

PEG Ratio

When adjusting for growth, ALKS's PEG of -158.88 indicates potential undervaluation.

-158.88

Price to Book

The market values Alkermes plc at 4.28 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.28

EV/EBITDA

Enterprise value stands at 39.50 times EBITDA. This signals the market has high growth expectations.

39.50

How Well Does ALKS Make Money?

Net Profit Margin

For every $100 in sales, Alkermes plc keeps $-0.02 as profit after all expenses.

-0.02%

Operating Margin

Core operations generate 3.66 in profit for every $100 in revenue, before interest and taxes.

3.66%

ROE

Management delivers $-0.02 in profit for every $100 of shareholder equity.

-0.02%

ROA

Alkermes plc generates $-0.01 in profit for every $100 in assets, demonstrating efficient asset deployment.

-0.01%

Following the Money - Real Cash Generation

Operating Cash Flow

Alkermes plc produces operating cash flow of $243.23M, showing steady but balanced cash generation.

$243.23M

Free Cash Flow

Alkermes plc generates strong free cash flow of $227.60M, providing ample flexibility for dividends, buybacks, or growth.

$227.60M

FCF Per Share

Each share generates $1.35 in free cash annually.

$1.35

FCF Yield

ALKS converts 2.82% of its market value into free cash.

2.82%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

15864.70

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-158.88

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.28

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.56

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.84

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.42

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.00

vs 25 benchmark

ROA

Return on assets percentage

-0.00

vs 25 benchmark

ROCE

Return on capital employed

0.02

vs 25 benchmark

How ALKS Stacks Against Its Sector Peers

MetricALKS ValueSector AveragePerformance
P/E Ratio15864.7031.66 Worse (Expensive)
ROE-0.02%501.00% Weak
Net Margin-0.02%-3647.00% (disorted) Weak
Debt/Equity0.84-0.30 (disorted) Distorted
Current Ratio2.425.78 Strong Liquidity
ROA-0.01%-262.00% (disorted) Weak

ALKS outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Alkermes plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

36.99%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

310.18%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

506.09%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ